Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ANTIGEN. Found 10 abstracts

Gollmer K, Asperti-Boursin F, Tanaka Y, Okkenhaug K, Vanhaesebroeck B, Peterson JR, Fukui Y, Donnadieu E, Stein JV. CCL21 mediates CD4(+) T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood. 2009 Jul;114(3):580-8.   PMCID: PMC2713469
Nozawa K, Ikeda K, Satoh M, Reeves WH, Stewart CM, Li YC, Yen TJ, Rios RM, Takamori K, Ogawa H, Sekigawa I, Takasaki Y, Chan EK. Autoantibody to NA14 is an independent marker primarily for Sjogren's syndrome. Frontiers in Bioscience. 2009 Jan;14:3733-9.   PMCID: PMCID: PMC2864436
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
Abraham N, Wan F, Montagnet C, Wong YN, Armstrong K. Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines. Journal of Urology. 2007 Jul;178(1):82-7.
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski J, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2007 May;25(15):2035-41.
Wang Y, Ylera F, Boston M, Kang SG, Kutok JL, Klein-Szanto AJ, Junghans RP. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Research and Treatment. 2007 Aug;104(2):129-44.
Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Academic radiology. 2004 Apr;11(4):368-76.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004 Feb;100(3):538-43.
Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Hazards of dose escalation in prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics. 2003 Dec;57(5):1260-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ANTIGEN

ANTIGEN KeyWords Plus: EXTERNAL-BEAM RADIATION radiotherapy IN-VIVO PREOPERATIVE NOMOGRAM prostate cancer CONFORMAL RADIATION-THERAPY dose escalation RADICAL PROSTATECTOMY OUTCOMES RESPONSES non-Hodgkin's lymphoma INTRAPERITONEAL CISPLATIN BIOCHEMICAL FAILURE PHASE-III TRIAL CENP-F PROGNOSTIC-SIGNIFICANCE THERAPY mortality LATE RECTAL TOXICITY PREDICTION in vivo metabolism CA-125 RHEUMATIC-DISEASES POSTTREATMENT EVALUATION RHEUMATOID-ARTHRITIS Group REGION GENE USAGE RECEPTOR SIGNALS CLINICAL UTILITY RISK CONFORMAL RADIOTHERAPY PROGNOSTIC MODELS breast cancer PACLITAXEL Autoantibody epithelial ovarian cancer LIBRARY resistance BIOCHEMICAL RECURRENCE plasma cell MITOSIS Protein PSA-DFS B-LYMPHOCYTES METABOLIC CHARACTERIZATION REPERTOIRE FOLLOW-UP ACTIVATION NA14 ANDROGEN DEPRIVATION THERAPY complications biochemical failure CARCINOMA Coiled-Coil treatment predictor prognostic models REVISED CRITERIA BONE-SCAN LYMPHOCYTE MOTILITY phospholipid intermediates MONOCLONAL-ANTIBODY prostate carcinoma GOLGI-COMPLEX repertoire HUMAN BRAIN VOLUME HISTOGRAMS CARBOPLATIN CENTROSOME EXPRESSION IgG P-31 MR spectroscopy Autoantigen ADENOCARCINOMA SEGMENTS TRENDS RECURRENCE drug sensitivity NATURAL-HISTORY RECEIPT focus prostatic neoplasms prostate-neoplasm staging-African Americans-practice guidelines DENDRITIC CELLS CUTTING EDGE B-CELL LYMPHOMA LOCAL RECURRENCE not otherwise specified (NOS) RANDOMIZED CONTROLLED-TRIAL STAGE-III POOR-PROGNOSIS PSA ERA SELECTION Gynecologic Oncology CHEMOKINES ADJUVANT SURVIVAL ADVANTAGE PRETREATMENT NOMOGRAM SCINTIGRAPHY metastasis CLASSIFICATION CA 125 tumor marker NUMA PROTEIN CANCER Sjogren's syndrome RANDOMIZED-TRIAL ANDROGEN DEPRIVATION PHOSPHOINOSITIDE 3-KINASE Review MAGNETIC-RESONANCE SPECTROSCOPY IRRADIATION SOMATIC HYPERMUTATION progression-free survival TRANSMEMBRANE DOMAIN PROTEIN
Last updated on Thursday, July 02, 2020